Zenotech Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 532039 | NSE: | Pharmaceuticals & Drugs | Small Cap

Zenotech Laboratorie Share Price

61.82 -0.06 -0.10%
as on 19-Mar'24 16:13

DeciZen - make an informed investing decision on Zenotech Laboratorie

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Zenotech Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
33.40
Market Cap:
377.7 Cr.
52-wk low:
45
52-wk high:
81

Is Zenotech Laboratories Ltd an attractive stock to invest in?

1. Is Zenotech Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Zenotech Laboratories Ltd is a below average quality company.

2. Is Zenotech Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Zenotech Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Zenotech Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zenotech Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Zenotech Laboratorie:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zenotech Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -41.8%-66.4%-77.1%932.9%-66.7%-5.9%10.9%-0.2%31.6%14.7%-
Value Creation
Index
-4.0NANANA-5.8-1.4-0.2-1.01.30.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2.84.12.12.311.1132622.536.642.439
Sales YoY Gr.-47.8%-49.5%9.2%395.1%17%99.7%-13.7%62.9%16%-
Adj EPS -6.2-8.4-5.2-5.8-1.9-0.51-0.23.61.91.9
YoY Gr.-NANANANANANA-119.2%NA-47.9%-
BVPS (₹) 0.9-7.5-12.7-18.26.96.48.17.911.613.514.7
Adj Net
Profit
-22.6-30.3-18.9-21.1-11.8-36.3-1.222.211.611
Cash Flow from Ops. -24.3-7.7-4.81.6-16.3-1411.45.717.720.7-
Debt/CF from Ops. -1.9-7-11.333.20-1.41.63.60.30-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 35.5%30.7%17.7%16%
Adj EPS NANA22%-47.9%
BVPS35.1%14.4%18.4%16.5%
Share Price 13.2% 22% 20.7% 23.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-154252.851.637.799.2-7.514.3-2.537.315.113.1
Op. Profit
Mgn %
-617-488.2-372.5-460.4-70.5-2634.528.447.848.850.4
Net Profit
Mgn %
-820.9-743.6-917.4-937.4-106.3-23.324.3-5.460.727.329.2
Debt to
Equity
14.4-2-1.2-0.800.50.40.40.10-
Working Cap
Days
832543842610148239125111767883
Cash Conv.
Cycle
297186252106-70-42-44-99-613

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 17.69%

Sales growth is good in last 4 quarters at 12.02%

Return on Equity has declined versus last 3 years average to 13.10%

Latest Financials - Zenotech Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 1.9 -2.1
TTM Sales (₹ Cr.) 38.6 6.6
BVPS (₹.) 14.7 0
Reserves (₹ Cr.) 29 62
P/BV 4.20 0.00
PE 33.40 0.00
From the Market
52 Week Low / High (₹) 45.00 / 81.00
All Time Low / High (₹) 3.99 / 173.59
Market Cap (₹ Cr.) 378
Equity (₹ Cr.) 61
Face Value (₹) 10
Industry PE 47.5

Management X-Ray of Zenotech Laboratorie:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Zenotech Laboratorie

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales3422111326223742
Operating Expenses 20241013191717161922
Manufacturing Costs722598981011
Material Costs3322111000
Employee Cost 6323556678
Other Costs 41543432222
Operating Profit -17-20-8-10-8-4961721
Operating Profit Margin (%) -629.0%-491.0%-389.0%-461.0%-70.6%-27.0%34.5%28.4%47.8%48.8%
Other Income 3000251011
Interest 5788201210
Depreciation 4444445677
Exceptional Items 0002006000
Profit Before Tax -23-30-19-20-12-311-11015
Tax 00000000-123
Profit After Tax -23-30-19-20-12-311-12212
PAT Margin (%) -829.0%-746.0%-929.0%-881.0%-106.0%-24.0%41.4%-5.4%60.6%27.3%
Adjusted EPS (₹)-6.3-8.4-5.3-5.5-1.9-0.51.8-0.23.61.9
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 3-27-46-66423950487182
Share Capital 34343434616161616161
Reserves -31-62-80-100-19-22-11-131021
Minority Interest0000000000
Debt44515151020192160
Long Term Debt00000002160
Short Term Debt4451515102019000
Trade Payables3245545223
Others Liabilities 203844603421131536
Total Liabilities 70645351828586868292

Fixed Assets

Gross Block83835255565970101105107
Accumulated Depreciation252948121621273441
Net Fixed Assets57534847444349747165
CWIP 000021729205
Investments 0000000000
Inventories4221110000
Trade Receivables0000022443
Cash Equivalents 6601291312211
Others Assets2222585347
Total Assets 70645351828586868292

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity -24-8-52-16-141161821
PBT -23-30-19-20-12-311-11015
Adjustment 811121050-2887
Changes in Working Capital -1012212-9-103-110
Tax Paid 10100000-1-1
Cash Flow From Investing Activity -105-1-3-16-21-5-2-6
Capex -100-1-4-18-22-5-2-6
Net Investments 0050-110000
Others 0000211000
Cash Flow From Financing Activity 307-1-14715-30-16-6
Net Proceeds from Shares 000012000000
Net Proceeds from Borrowing 0000-30-120-15-6
Interest Paid -1-1-1-1-19-5-1-2-10
Dividend Paid 0000000000
Others 31700-512010200
Net Cash Flow 5-10028-15-12109
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)-155.73N/AN/AN/A0-7.7324.35-2.4837.2615.15
ROCE (%)-39.28N/AN/AN/A-61.88-5.9518.320.4815.2618.39
Asset Turnover Ratio0.050.070.040.040.170.160.310.260.440.49
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/A1N/A0.821.75
Working Capital Days
Receivable Days920622803330463931
Inventory Days35724030220329205110
Payable Days5573035941,0262,4102,4243,154000

Zenotech Laboratories Ltd Stock News

Zenotech Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Zenotech Laboratorie on 19-Mar-2024 16:13 is ₹61.82.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Mar-2024 16:13 the market cap of Zenotech Laboratorie stood at ₹377.7.
The latest P/E ratio of Zenotech Laboratorie as of 19-Mar-2024 16:13 is 33.40.
The latest P/B ratio of Zenotech Laboratorie as of 19-Mar-2024 16:13 is 4.20.
The 52-week high of Zenotech Laboratorie is ₹81.00 and the 52-week low is ₹45.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zenotech Laboratorie is ₹38.63 ( Cr.) .

About Zenotech Laboratories Ltd

Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.

The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.

Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.

Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.

Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.

Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.

Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.

Product range of the company includes:

Generics -- Biological

  • Nugraf
  • Macrogen

        Chemical

  • Gemcitabine for Injection 
  • Paclitaxel for Injection 
  • Docetaxel for Injection 
  • Irinotecan for Injection 
  • Oxaliplatin for Injection 
  • Epirubicin for Injection 
  • Bleomycin for Injection 
  • Cisplatin for Injection 
  • Carboplatin for Injection 
  • Ifosfamide for Injection 
  • Etoposide for Injection

New biologicals Zenotech develops new biological entities in the areas of

  • Cancer
  • Neurology
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.